<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Anz, David</dc:creator>
  <dc:creator>Mueller, Wolfgang</dc:creator>
  <dc:creator>Golic, Michaela</dc:creator>
  <dc:creator>Kunz, Wolfgang G.</dc:creator>
  <dc:creator>Rapp, Moritz</dc:creator>
  <dc:creator>Koelzer, Viktor H.</dc:creator>
  <dc:creator>Ellermeier, Jonathan</dc:creator>
  <dc:creator>Ellwart, Joachim W.</dc:creator>
  <dc:creator>Schnurr, Max</dc:creator>
  <dc:creator>Bourquin, Carole</dc:creator>
  <dc:creator>Endres, Stefan</dc:creator>
  <dc:date>2012-04-01</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Regulatory T cells (Treg) mediate tolerance towards self-antigens by suppression of innate and adaptive immunity. In cancer patients, tumor-infiltrating FoxP3+ Treg suppress local anti-tumor immune responses and are often associated with poor prognosis. Markers that are selectively expressed on tumor-infiltrating Treg may serve as targets for immunotherapy of cancer. Here we show that CD103, an integrin mediating lymphocyte retention in epithelial tissues, is expressed at high levels on tumor-infiltrating FoxP3+ Treg in several types of murine cancer. In the CT26 model of colon cancer up to 90% of the intratumoral FoxP3+ cells expressed CD103 compared to less than 20% in lymphoid organs. CD103+ Treg suppressed T effector cell activation more strongly than CD103&lt;sup&gt;neg&lt;/sup&gt; Treg. Expression of CD103 on Treg closely correlated with intratumoral levels of transforming growth factor β (TGF-β) and could be induced in a TGF-β-dependent manner by tumor cell lines. &lt;em&gt;In vivo&lt;/em&gt;, gene silencing of TGF-β reduced the frequency of CD103+ Treg, demonstrating that CD103 expression on tumor-infiltrating Treg is driven by intratumoral TGF-β. Functional blockade of CD103 using a monoclonal antibody did however not reduce the number of intratumoral Treg, indicating that CD103 is not involved in homing or retention of FoxP3+ cells in the tumor tissue. In conclusion, expression of CD103 is a hallmark of Treg that infiltrate TGF-β-secreting tumors. CD103 thus represents an interesting target for selective depletion of tumor-infiltrating Treg, a strategy that may help to improve anti-cancer therapy.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/unifr/documents/302809</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/302809/files/bou_cht.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1002/ijc.25902</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>International Journal of Cancer. - 2012, vol. 129, no. 10, p. 2417–2426</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">CD103</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">regulatory T cell</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">FoxP3</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">tumor</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns5="xml" ns5:lang="en">CD103 is a hallmark of tumor-infiltrating regulatory T cells</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>